Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Abstracto

Harnessing the Power of Targeted RNA Therapies for Cancer Treatment and Immunomodulation

Zhuoran Yu

Targeted RNA therapies have emerged as a promising frontier in the quest for more effective and personalized approaches to cancer treatment and immunomodulation. This article explores the potential of RNA-based therapies in both contexts, highlighting their precision and versatility. Small interfering RNA (siRNA) and microRNA (miRNA) therapies can selectively silence or regulate genes associated with cancer, while messenger RNA (mRNA) vaccines hold promise for training the immune system to combat malignancies. In the realm of immunomodulation, RNA-based strategies like CAR-T cell therapy and immune checkpoint inhibitors are revolutionizing cancer care. Challenges in delivery and off-target effects persist, but ongoing research and innovation are paving the way for a brighter future where RNA therapies become integral components of comprehensive cancer treatment.